Research programme: metabolic disorders therapeutics - Xenon

Drug Profile

Research programme: metabolic disorders therapeutics - Xenon

Alternative Names: Metabolic disorders therapy research programme - Xenon; Metabolic syndrome therapy research programme - Xenon; Obesity therapy research programme - Xenon; Research programme: metabolic syndrome therapy - Xenon; Research programme: obesity therapy - Xenon; XEN-103

Latest Information Update: 02 Jun 2010

Price : $50

At a glance

  • Originator Xenon Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action Stearoyl CoA desaturase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Metabolic syndrome; Obesity

Most Recent Events

  • 02 Jun 2010 Preclinical development is ongoing in Canada
  • 20 Sep 2005 This programme is still in active development - BIO 2005: Annual International Convention (BIO 2005)
  • 21 Sep 2004 Xenon Pharmaceuticals and Novartis Pharma have entered into an agreement to research, develop and commercialise compounds from Xenon's research programme
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top